Does Centene Corporation Cover Forteo? A Woman's Guide to Getting Teriparatide Approved

What Is Forteo and Why Do Women Need It?

Forteo (teriparatide) is an anabolic bone agent, meaning it builds new bone rather than just slowing bone loss. That distinction matters for women because the two most common scenarios that bring a woman to this drug are postmenopausal osteoporosis with fracture, and long-term glucocorticoid use (common in autoimmune conditions that disproportionately affect women).

Teriparatide is a recombinant form of human parathyroid hormone (1-34) that stimulates osteoblast activity. Given daily by subcutaneous injection, it is approved by the FDA for up to 24 months of continuous use over a patient's lifetime. After the course ends, an antiresorptive drug such as a bisphosphonate or denosumab is required to preserve the gains.

Who Gets Prescribed Forteo?

The FDA-approved indications include:

• Postmenopausal women with osteoporosis at high fracture risk
• Men with primary or hypogonadal osteoporosis
• Women and men with glucocorticoid-induced osteoporosis at high fracture risk
• Women who have failed or cannot tolerate other osteoporosis therapies

For women specifically, the Fracture Prevention Trial showed teriparatide reduced vertebral fracture risk by 65% and nonvertebral fracture risk by 53% in postmenopausal women with prior vertebral fracture. Those numbers are why clinicians fight hard to get it covered.

Bone Loss Across a Woman's Life

Bone loss is not a single event. Women lose bone fastest in the two years before and the two years after the final menstrual period, a window when estrogen decline accelerates bone turnover by 3 to 5 times the premenopausal rate. By the time a woman is five years postmenopausal, she may have lost 10 to 15% of her trabecular bone mass. For women who enter perimenopause with pre-existing low bone density (common in PCOS, long-term depot medroxyprogesterone use, amenorrhea from hypothalamic dysfunction, or anorexia history), Forteo may be relevant earlier than typical.

How Centene's Formulary System Works

Centene Corporation is the parent company of many state Medicaid managed-care plans and some Affordable Care Act Marketplace plans. The brand names you may know include Ambetter (Marketplace), WellCare (Medicare and Medicaid), Sunshine Health, Peach State Health Management, and others. Each subsidiary maintains its own formulary, but they share common corporate pharmacy benefit management structures.

Tier Placement and Cost-Sharing

Specialty drugs like Forteo are almost always Tier 3 or Tier 4. On Centene Medicaid plans, your out-of-pocket cost may be near zero if you meet Medicaid income thresholds. On Ambetter Marketplace plans, a Tier 4 specialty drug can carry a 30 to 50% coinsurance after deductible, which on a drug that costs roughly $3,200 per month without assistance translates to a significant personal cost. Always call the member services number on the back of your insurance card and ask specifically: "What is my cost-share for Forteo after prior authorization approval?"

Prior Authorization Criteria: What Centene Typically Requires

Centene's prior authorization criteria for teriparatide vary by subsidiary and plan year, but the shared framework across most plans requires documentation of:

1. A DEXA scan showing a T-score of <-2.5, or a fragility fracture history even with a T-score above that threshold
2. A diagnosis of postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, or documented intolerance or contraindication to bisphosphonates
3. Step therapy: evidence that the patient has tried and failed (defined as a new fracture on therapy, or documented intolerance such as esophageal disease, severe renal impairment with GFR <35, or osteonecrosis of the jaw) at least one bisphosphonate, such as alendronate or risedronate
4. Confirmation the prescriber is an appropriate specialist (endocrinologist, rheumatologist, OB-GYN, or primary care physician with documented osteoporosis expertise)
5. Confirmation the patient has not previously received a full 24-month lifetime course of teriparatide or abaloparatide (Tymlos)

The framework above is WomanRx's synthesis of publicly available Centene subsidiary prior authorization criteria documents and clinical practice guidelines from The Menopause Society and AACE. Individual plan criteria may differ. Always request a copy of the actual PA criteria from your specific plan before submitting.

Step-by-Step: How to Get Centene to Approve Forteo

Step 1: Confirm Your Plan's Formulary

Go to the formulary lookup tool on your specific Centene subsidiary's website (for example, Ambetter or WellCare), enter "teriparatide" or "Forteo," and confirm it is listed. If it is not listed, ask your prescriber to request a formulary exception, which is a separate process from a standard prior authorization.

Step 2: Ask Your Prescriber to Submit a Complete PA Request

The single most common reason for a first-round PA denial is incomplete documentation. The PA submission should include:

• Your most recent DEXA scan report with T-scores at the spine and hip
• Fracture history, including any imaging reports confirming vertebral fractures
• A list of prior osteoporosis medications with dates of use and the specific reason they failed or were discontinued
• Any labs showing contraindications to bisphosphonates (for example, a serum creatinine showing GFR <35)
• A letter of medical necessity from your prescriber that explicitly maps your clinical situation to the plan's PA criteria language

Step 3: If Denied, File a Formal Appeal

A first denial is not a final answer. Under the ACA and Medicaid rules, you have the right to an internal appeal and, if that fails, an external independent review. The ACA mandates that health plans provide a full and fair review of coverage denials. For time-sensitive situations (such as a woman who has just had a fragility fracture), you can request an expedited appeal, which requires a decision within 72 hours on most plans.

The appeal letter should include the Endocrine Society Clinical Practice Guideline on osteoporosis, the fracture risk reduction data from the Fracture Prevention Trial, and a direct statement from your prescriber explaining why bisphosphonate step therapy is either medically contraindicated or has already been exhausted.

Step 4: Apply for Lilly's Patient Assistance Program

While the appeal is pending, ask your prescriber's office or a specialty pharmacy to submit an application to Lilly Cares Foundation, Eli Lilly's patient assistance program. Women who meet income criteria may receive Forteo at no cost while coverage is being resolved. Income thresholds and eligibility change annually; verify directly with Lilly Cares.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know Before Starting Forteo

This section is required reading if you are under age 55 or have any possibility of pregnancy.

Pregnancy

Teriparatide is contraindicated in pregnancy. Animal reproduction studies showed skeletal abnormalities in offspring at doses higher than the human therapeutic dose. There are no adequate, well-controlled studies in pregnant women, and the drug should not be used during pregnancy under any circumstances. If you become pregnant while taking Forteo, stop the drug immediately and contact your prescriber.

Women of reproductive age being considered for teriparatide should have a negative pregnancy test before starting and should use reliable contraception for the entire 24-month course. This is particularly relevant for:

• Perimenopausal women who have not yet confirmed menopause (12 consecutive months without a period)
• Women with PCOS who have irregular cycles and may not recognize a pregnancy promptly
• Women with premature ovarian insufficiency who have been told conception is unlikely but not impossible

Lactation

It is not known whether teriparatide is excreted in human breast milk. Given the mechanism of action and the availability of alternative treatments for osteoporosis in younger women, teriparatide should not be used during breastfeeding. The LactMed database does not list sufficient human data to establish safety. Discuss timing with your prescriber if you are in the postpartum period.

Postpartum Bone Loss

Postpartum and lactation-associated osteoporosis is a rare but real condition that can cause vertebral fractures in young women. Most cases resolve spontaneously after weaning, and teriparatide has been used off-label in severe cases after lactation has ended. If you experienced fragility fractures during pregnancy or the postpartum period, ask your OB-GYN or endocrinologist about specialist referral once you have finished breastfeeding.

Who This Treatment Is Right For (and Who It Is Not)

Women Who Are Strong Candidates

• Postmenopausal women (typically age 50 and older) with a T-score of <-2.5 at the spine or hip, or a prior fragility fracture, who have already tried a bisphosphonate for at least 12 months and experienced a new fracture or cannot tolerate it
• Women with glucocorticoid-induced osteoporosis taking prednisone equivalent of 7.5 mg/day or more for 3 months or longer, where fracture risk is high per ACR guidelines
• Women with very low T-scores (below -3.0) and multiple fractures where the fracture risk reduction from an anabolic agent is expected to outweigh the complexity of daily injection

Women for Whom Forteo Is Not Appropriate

• Any woman who is pregnant or trying to conceive
• Women with hypercalcemia (teriparatide raises serum calcium transiently)
• Women with Paget's disease of bone or a history of skeletal radiation
• Women with bone metastases or a history of primary bone cancer
• Women who have already completed a 24-month lifetime course of teriparatide or abaloparatide
• Women with unexplained alkaline phosphatase elevation, which may indicate underlying bone disease that needs evaluation before starting

Life-Stage Considerations

Reproductive years (under 40): Osteoporosis in younger women almost always signals an underlying cause: hypothalamic amenorrhea, anorexia, celiac disease, inflammatory bowel disease, long-term depot contraception, or glucocorticoid use. ACOG Practice Bulletin on bone health recommends identifying and treating the underlying cause first. Teriparatide is rarely indicated in this group except for severe glucocorticoid-induced osteoporosis.

Perimenopause (typically 45 to 55): The 2023 Menopause Society Position Statement on Hormone Therapy notes that menopausal hormone therapy (MHT) is first-line for bone protection in symptomatic perimenopausal women under 60. Teriparatide is reserved for high-fracture-risk cases where MHT alone is insufficient or declined.

Postmenopause: This is the primary target population. Women more than 5 years postmenopausal with a prior vertebral fracture and T-score <-2.5 represent the clearest indication. Sequential therapy (teriparatide followed by a bisphosphonate or denosumab) is the standard approach per Endocrine Society guidelines.

The PCOS and Bone Connection

Women with PCOS have a complex relationship with bone density. Androgen excess may partially protect bone, but irregular cycles and prolonged periods of low estrogen (especially in lean PCOS phenotypes) can lead to suboptimal peak bone mass. A 2021 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS showed no statistically significant difference in overall BMD compared to controls, but subgroup analysis of lean women with oligomenorrhea suggested lower lumbar spine BMD. If you have PCOS, irregular periods, and a history of disordered eating or very low BMI, ask your provider for a DEXA scan earlier than the standard postmenopausal screening age.

Evidence Gaps: What We Do and Do Not Know in Women

Women have been the primary subjects in teriparatide trials, which is one area where women's-health research is ahead of the general curve. The Fracture Prevention Trial enrolled postmenopausal women almost exclusively. However, several gaps remain:

• Perimenopausal women: Nearly all trial data comes from women who are at least 5 years postmenopausal. The optimal timing for starting teriparatide in the perimenopause is not well defined.
• Younger women with secondary osteoporosis: Data on teriparatide in premenopausal women with glucocorticoid-induced osteoporosis is based on smaller trials and observational data, not the large RCT base that exists for postmenopausal use.
• Racial and ethnic diversity: The Fracture Prevention Trial enrolled a predominantly white population. Fracture risk calculators like FRAX have been questioned for their accuracy in Black and Hispanic women, who have different baseline BMD and fracture risk profiles. Centene plans serve a disproportionately Medicaid-insured population with significant racial diversity; extrapolating trial results without acknowledging this limitation is not appropriate.
• Sequential therapy timing: How long to wait after teriparatide before starting a bisphosphonate, and which bisphosphonate performs best after an anabolic course, is still being studied in trials like DATA-Switch.

Alternatives If Centene Denies Forteo

If Centene denies Forteo after appeal, you and your prescriber have several options:

Abaloparatide (Tymlos): A related anabolic PTH-related protein analog, also requiring prior authorization but sometimes approved when teriparatide is denied, since it is a different molecule. The ACTIVE trial showed an 86% reduction in vertebral fracture risk versus placebo in postmenopausal women.

Romosozumab (Evenity): A sclerostin inhibitor with a dual mechanism (builds bone and slows resorption). It requires prior authorization and carries a black-box warning about cardiovascular events. The FRAME trial showed a 73% reduction in new vertebral fractures at 12 months in postmenopausal women.

Denosumab (Prolia): An antiresorptive injection given every 6 months. Not anabolic, but generally easier to get covered and appropriate for women with renal impairment who cannot take bisphosphonates. Denosumab must not be stopped abruptly without transitioning to a bisphosphonate, as rapid bone loss and multiple vertebral fractures can occur.

Bisphosphonate optimization: If your prescriber believes you truly need an anabolic agent but Centene refuses, document that opinion in writing. It strengthens any future appeal or grievance.

Sample Language for a Letter of Medical Necessity

Your prescriber can adapt this language for the PA or appeal submission:

"[Patient name] is a [age]-year-old postmenopausal woman with a T-score of [X] at the lumbar spine and a documented fragility fracture of [location] in [year]. She completed [duration] of alendronate 70 mg weekly, which was discontinued due to [GI intolerance / new fracture on therapy / contraindication]. Per the Fracture Prevention Trial (NEJM 2001) and Endocrine Society 2019 Clinical Practice Guideline, teriparatide is medically necessary and represents the standard of care for her fracture risk profile. No equivalent alternative is clinically appropriate for the reasons stated above."

Frequently Asked Questions